Pharmacokinetics and Half-Life of Protein Therapeutics

Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives

Volumn , Issue , 2012, Pages 23-38

  Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bioavailability; Distribution; Drug concentration; Elimination; Half life modulation; Pharmacokinetics; Plasma concentration time profile; Therapeutic proteins

Indexed keywords

EID: 84886160521     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527644827.ch2     Document Type: Chapter

References (28)

1. Meibohm, B., and Evans, W.E. (2006) Clinical pharmacodynamics & pharmacokinetics, in Textbook of Therapeutics: Drug and Disease Management (eds R.A. Helms and D.J. Quan), Lippincott Williams Wilkins, Philadelphia, PA, pp. 1-30.
2. Tang, L., Persky, A.M., Hochhaus, G., and Meibohm, B. (2004) Pharmacokinetic aspects of biotechnology products . J. Pharm. Sci., 93, 2184-2204 .
3. van de Waterbeemd, H., and Gifford, E. (2003) ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov., 2, 192-204 .
4. Tang, L., and Meibohm, B. (2006) Pharmacokinetics of peptides and proteins, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (ed. B. Meibohm), Wiley-VCH Verlag GmbH, Weinheim, pp. 17-44 .
5. Lesko, L.J. (2007) Paving the critical path: how can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther., 81, 170-177 .
6. Meibohm, B., and Derendorf, H. (2002) Pharmacokinetic/pharmacodynamic studies in drug product development . J. Pharm. Sci., 91, 18-31 .
7. Suryawanshi, S., Zhang, L., Pfi ster, M., and Meibohm, B. (2010) The current role of model-based drug development . Expert Opin. Drug Discov., 5, 311-321 .
8. Herbst, R.S., Kim, E.S., and Harari, P.M. (2001) IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer . Expert Opin. Biol. Ther., 1, 719-732 .
9. Mahato, R.I., Narang, A.S., Thoma, L., and Miller, D.D. (2003) Emerging trends in oral delivery of peptide and protein drugs . Crit. Rev. Ther. Drug Carrier Syst., 20, 153-214 .
10. Shen, W.C. (2003) Oral peptide and protein delivery: unfulfi lled promises? Drug Discov. Today, 8, 607-608 .
11. Lee, H.J. (2002) Protein drug oral delivery: the recent progress . Arch. Pharm. Res., 25, 572-584 .
12. Meibohm, B., and Braeckman, R.A. (2007) Pharmacokinetics and pharmacodynamics of peptides and proteins, in Pharmaceutical Biotechnology: Concepts and Applications (eds D.J.A. Crommelin, R.D. Sindelar, and B. Meibohm), Informa Healthcare, New York, pp. 95-123 .
13. Zito, S.W. (1997) Pharmaceutical Biotechnology: A Programmed Text, Technomic Pub. Co., Lancaster, PA .
14. Flessner, M.F., Lofthouse, J., and Zakaria, R. (1997) In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal . A m. J. Physiol., 273, H2783-H2793 .
15. Reddy, S.T., Berk, D.A., Jain, R.K., and Swartz, M.A. (2006) A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles . J. Appl. Physiol., 101, 1162-1169 .
16. Colburn, W. (1991) Peptide, peptoid, and protein pharmacokinetics/ pharmacodynamics, in Petides, Peptoids, and Proteins, vol. 3, (eds P. Garzone, W. Colburn, and M. Mokotoff), Harvey Whitney Books, Cincinnati, OH, pp. 94-115 .
17. Kageyama, S., Yamamoto, H., Nakazawa, H., Matsushita, J., Kouyama, T., Gonsho, A., Ikeda, Y., and Yoshimoto, R. (2002) Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys . Arterioscler. Thromb. Vasc. Biol., 22, 187-192 .
18. Straughn, A.B. (2006) Limitations of noncompartmental pharmacokinetic analysis of biotech drugs, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (ed. B. Meibohm), Wiley-VCH Verlag GmbH, Weinheim, pp. 181-188 .
19. Perrier, D., and Mayersohn, M. (1982) Noncompartmental determination of the steady-state volume of distribution for any mode of administration . J. Pharm. Sci., 71, 372-373 .
20. Straughn, A.B. (1982) Model-independent steady-state volume of distribution . J. Pharm. Sci., 71, 597-598 .
21. Deen, W.M., Lazzara, M.J., and Myers, B.D. (2001) Structural determinants of glomerular permeability . Am. J. Physiol. Renal Physiol., 281, F579-F596 .
22. Meibohm, B., and Derendorf, H. (2004) Pharmacokinetics and pharmacodynamics of biotech drugs, in Pharmaceutical Biotechnology: Drug Discovery and Clinical Appications (eds R. Muller and O. Kayser), Wiley-VCH Verlag GmbH, Weinheim, pp. 147-172 .
23. Mager, D.E. (2006) Target-mediated drug disposition and dynamics . Biochem. Pharmacol., 72, 1-10 .
24. Bauer, R.J., Gibbons, J.A., Bell, D.P., Luo, Z.P., and Young, J.D. (1994) Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats . J. Pharmacol. Exp. Ther., 268, 152-158 .
25. Roopenian, D.C., and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age . Nat. Rev. Immunol., 7, 715-725 .
26. Wang, W., Wang, E.Q., and Balthasar, J.P. (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics . Clin. Pharmacol. Ther., 84, 548-558 .
27. Dirks, N.L., and Meibohm, B. (2010) Population pharmacokinetics of therapeutic monoclonal antibodies . Clin. Pharmacokinet., 49, 633-659 .
28. Kim, J., Hayton, W.L., Robinson, J.M., and Anderson, C.L. (2007) Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplifi ed mechanism-based model . Clin. Immunol., 122, 146-155 .